People
Jazz Pharmaceuticals names new directors
18 November 2020 -

Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a global biopharmaceutical company, has named Jennifer Cook and Mark D. Smith, MD as its new Directors effective 1 December 2020, it was reported on Tuesday.

Cook joins the company as a Class II director and will be up for election at the company's 2022 annual meeting. She was the chief executive officer at GRAIL Inc and has held a number of senior management positions at Roche. She has managed the company's United States Immunology and Ophthalmology Business Unit and has headed Roche's European commercial business. She has also held the position of global head of Clinical Operations at Roche. Presently, she serves as non-executive director on the boards of two publicly-held biotechnology companies, Denali Therapeutics Inc and BridgeBio Pharma Inc. She also serves on the board of Ambys Medicines Inc.

Dr Smith joins the company as a Class I director and will be up for election at the company's 2021 annual meeting. He is a professor of clinical medicine at the University of California at San Francisco. He was the founding president and chief executive officer of the California HealthCare Foundation and has served as executive vice president at the Henry J. Kaiser Family Foundation. Presently, he serves as non-executive director on the boards of Phreesia Inc and Teladoc Health Inc. He also serves on the board of The Commonwealth Fund.

Login
Username:

Password: